Diabetol Metab Syndr 5: 47, 2013
Key outcomes: Mean weight loss: 14.9% (vs 2.4% placebo) 86.4% of participants achieved 5% loss (vs 31.5% placebo) 50.5% achieved 15% loss (vs 4.9% placebo) SELECT (Lincoff et al., NEJM 2023) added the cardiovascular signature: in 17,604 non-diabetic adults with prior CV history, semaglutide 2.4 mg reduced MACE (CV death, MI, stroke) by 20% over 3 years
Research shows that creatine monohydrate in this form stays stable for a long time, possibly up to three years, based on how much creatine breaks down into creatinine
Semaglutide is administered as a weekly injection that you give yourself in the privacy of your home, typically in the stomach area, thigh, or upper arm
The mesolimbic reward system represents a third mechanism through which GLP-1 affects eating behavior